Newborn screening for all identifiable disorders with tandem mass spectrometry is cost effective: Supporting arguments

Bradford L. Therrell, Colleen Buechner

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Tandem mass spectrometry (MS/MS) has become increasingly popular as the preferred technology for detecting inborn errors of metabolism in newborn screening (NBS) programmes. Its sensitivity and specificity for detecting numerous metabolic conditions is well-documented. As a NBS technology, there are continuing questions about whether MS/MS should be utilised to the fullest when such usage may mean detecting and reporting analytical findings that could lead to differentiating and diagnosing for which treatment efficacy may not yet be proven. As part of a friendly debate to educate conference attendees on both sides of a somewhat controversial issue, 2 papers awere presented giving information supporting or questioning the cost effectiveness of full scan usage and reporting when using MS/MS in NBS. Reported here are some of the supporting arguments.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalAnnals of the Academy of Medicine Singapore
Volume37
Issue number12 SUPPL.
StatePublished - Dec 1 2008

Keywords

  • Cost effectiveness
  • Newborn screening
  • Tandem mass spectrometry

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Newborn screening for all identifiable disorders with tandem mass spectrometry is cost effective: Supporting arguments'. Together they form a unique fingerprint.

Cite this